Dissemination of additional risk minimisation measures for patients and healthcare professionals in EU/EEA countries

First published: 09/06/2025

Last updated: 09/06/2025





Administrative details

EU PAS number
EUPAS100000524
Study ID
1000000524
DARWIN EU® study
No
Study countries
Finland
Hungary
Italy

Lithuania
☐ Netherlands
Romania
Study status
Ongoing
Research institutions and networks
Institutions
University of Naples Federico II
First published: 01/02/2024
Last updated: 01/02/2024
Institution
Netherlands Institute for Health Services Research
(Nivel)
Netherlands
First published: 01/02/2024
Last updated: 01/02/2024
Institution Not-for-profit

Contact details

Study institution contact

Anne Brabers a.brabers@nivel.nl

Study contact

a.brabers@nivel.nl

Primary lead investigator

Liset Van Dijk

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 28/02/2025

Study start date

Actual: 28/02/2025

Date of interim report, if expected

Planned: 28/04/2026

Date of final study report

Planned: 29/06/2026

Sources of funding

EMA

Study protocol

ROC30 Annex V Response template Nivel 16012025 DEF.pdf(868.54 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Data collection methods:

Study design:

Focus groups, interviews, and surveys among the different populations, desk research

Main study objective:

- 1. To describe and analyse aRMM dissemination: Process & frequency; key stakeholders involved; roles & responsibilities by type of aRMM, by dissemination method, by medicinal product and by country
- 2. To describe and analyse how access is ensured by type of aRMM, by medicinal product, by key stakeholder involved, and by country
- 3. To identify key challenges of disseminating healthcare professional- and patient-targeted aRMMs by type of aRMM, by dissemination method, by key stakeholder involved and by country
- 4. To identify and describe preferences for aRMM tools by type of aRMM, by dissemination method, by key stakeholder involved and by country
- 5. To provide recommendations by identifying feasible and concrete steps at each step of implementation pathway

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Name of medicine

XELJANZ

AUBAGIO

LEMTRADA

EYLEA

Name of medicine, other

Valproate containing medicinal products

Retinoids containing medicinal products

Study drug International non-proprietary name (INN) or common name

TOFACITINIB CITRATE

TERIFLUNOMIDE

ALEMTUZUMAB

AFLIBERCEPT

EDOXABAN

ACITRETIN

ADAPALENE

ALITRETINOIN

BEXAROTENE

ISOTRETINOIN

TRETINOIN

TAZAROTENE

Population studied

Short description of the study population

Patients using these drugs, HCPs prescribing these drugs, Competent Authorities, pharmacists, Marketing AuthorizationHolders (MAH)

Data management

ENCOPP Soal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No